We should formally the test the hypothesis that inhibitors of the renin-angiotensin-aldosterone system (RAAS), through effects on glomerular pressure and cardiac remodeling, are preferable to other antihypertensive classes for the treatment of post-donation hypertension. Here, REN is linked to Hypertension.